Choose Your Country or Region

Anti-Caspase-3 p12 Rabbit Antibody [N15D21]

Catalog No.: F2459

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000 IHC1:2000 IF1:150

Application
WB, IHC, IF , FCM

Reactivity
Mouse, Rat, Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
32, 29, 12 kDa 12 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Datasheet & SDS

Biological Description

Specificity
Anti-Caspase-3 p12 Rabbit Antibody [N15D21] detects endogenous levels of total Caspase-3 p12 protein.

Clone
N15D21

Synonym(s)
CPP32, CASP3, Caspase-3, CASP-3, Apopain, Cysteine protease CPP32, Protein Yama, SREBP cleavage activity 1, CPP-32, SCA-1

Background
Caspase-3 p12 is the small subunit of caspase-3, a key executioner protease in the apoptotic pathway. Caspase-3 is initially synthesized as an inactive 32 kDa zymogen, procaspase-3, which undergoes proteolytic cleavage to generate two subunits: a 17 kDa large subunit (p17) and a 12 kDa small subunit (p12). These subunits combine to form an active heterotetramer capable of executing the final stages of apoptosis by cleaving a variety of cellular substrates. The active site of caspase-3 is primarily formed by catalytic residues from the p17 subunit, while the p12 subunit is crucial for substrate recognition and stabilizing the active enzyme complex. Caspase-3 preferentially cleaves substrates containing an aspartic acid at the P1 position, with the DEVD sequence being a primary target. Caspase-3 functions as initiating chromatin condensation, DNA fragmentation, and the disassembly of cytoskeletal structures during apoptosis. Its activity is tightly controlled through several mechanisms: it is initially synthesized as an inactive proenzyme, activated by initiator caspases like caspase-8 and caspase-9, and inhibited by endogenous regulators or post-translational modifications such as nitrosylation. Upon activation, caspase-3 translocates to the nucleus, which is essential for the progression of apoptosis. Dysregulation of caspase-3 activity is implicated in diseases like cancer and neurodegenerative disorders.

Background

Caspase-3 p12 is the small subunit of caspase-3, a key executioner protease in the apoptotic pathway. Caspase-3 is initially synthesized as an inactive 32 kDa zymogen, procaspase-3, which undergoes proteolytic cleavage to generate two subunits: a 17 kDa large subunit (p17) and a 12 kDa small subunit (p12). These subunits combine to form an active heterotetramer capable of executing the final stages of apoptosis by cleaving a variety of cellular substrates. The active site of caspase-3 is primarily formed by catalytic residues from the p17 subunit, while the p12 subunit is crucial for substrate recognition and stabilizing the active enzyme complex. Caspase-3 preferentially cleaves substrates containing an aspartic acid at the P1 position, with the DEVD sequence being a primary target. Caspase-3 functions as initiating chromatin condensation, DNA fragmentation, and the disassembly of cytoskeletal structures during apoptosis. Its activity is tightly controlled through several mechanisms: it is initially synthesized as an inactive proenzyme, activated by initiator caspases like caspase-8 and caspase-9, and inhibited by endogenous regulators or post-translational modifications such as nitrosylation. Upon activation, caspase-3 translocates to the nucleus, which is essential for the progression of apoptosis. Dysregulation of caspase-3 activity is implicated in diseases like cancer and neurodegenerative disorders.

References
https://pubmed.ncbi.nlm.nih.gov/34342377/ https://pubmed.ncbi.nlm.nih.gov/17594508/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%